Two international profiles, experienced in orthopedics and cell therapy
Download the free guide
Boost your gains
Gosselies, Belgium, may 29, 2017, 7: 00 am – BONE THERAPEUTICS (code Euronext Brussels and Paris : BOTHE, eligible PEA-PME) society of cellular therapy bone that meets major unmet medical needs in the areas of orthopedics and bone diseases, announces today the appointment of Steve Swinson and Damian Brown as independent directors. Their appointments took effect on may 26, 2017.
Steve Swinson, and Damian Marron, by their knowledge and their expertise in specific publicly traded companies in the sector of orthopedics and cell therapy, complementing the expertise of the Board of directors of Bone Therapeutics, while bringing their expertise to the management team. They will replace Jacques Reymann and Jean-Jacques Verdickt.
Steve Swinson has held many positions of responsibility in companies of medical technologies in orthopedics, and has notably been in charge of the general management, strategy, sales, marketing and business operations of Medtronic International, the international leader in medical technology. At Medtronic, Steve Swinson was head of the division Spine & Biologics for Canada as well as western Europe, and has been Vice-President and General Manager of international activities related to the spine with the responsibility of a turnover substantial.
During his international career, rich of 30 years in Asia, the United States, Europe and Africa, he has also occupied positions of responsibility in departments and medical diagnosis within multinational major engineering, such as General Electric and Hewlett Packard. Steve holds a phd in electrical engineering from the University of Manchester and an MBA from the University of Chicago.
Damian Brown is a senior executive experienced in the field of life sciences, with a strong balance sheet in terms of value creation. He has successfully led projects in the financing of publicly listed and private companies, in the management of development programmes and recovery in mergers and acquisitions, license agreements and research partnerships and commercialization. He has specific skills in the areas of cell therapy, immuno-oncology and orphan diseases. More recently, he has been ceo of Agalimmune and TxCell, a French biotech company specializing in immunotherapeutics cellular custom from T-cells, which he has led the ipo on Euronext Paris. As the ceo of Trophos, France, he has helped to raise 34 Million financing to accelerate the development of the society, which eventually will be acquired by Roche for a price of 700 M. Damian has also been Executive Vice-President in charge of development at NicOx, assistant to the Director-General within the framework of various fund-raising for a total amount in excess of 175 M.
Michel Helbig de Balzac, President of the Board of directors of Bone Therapeutics, said : “We are very pleased to welcome Steve and Damian to the Board of directors of Bone Therapeutics. Their combined balance sheet in terms of management and value creation in the field of health, their knowledge of the sector, as well as their respective expertise in the medical technology, orthopaedic and cellular therapy, will be a major asset for the Company. Their policy recommendations will be valuable for the leadership team at a time when efforts should be focused on the progress of our innovative platform of cellular therapy allogeneic to the marketing. We extend our appreciation to Jacques Reymann and Jean-Jacques Verdickt for their dedication during the many years he spent at Bone Therapeutics, and we wish them the best for the rest “.
About his appointment, Steve Swinson commented : “Bone Therapeutics is the leader in regenerative approaches in orthopedics and bone diseases, and its platform of cellular therapy allogeneic has the potential to revolutionize medicine in these areas. I am very excited about the opportunity that is given to me to be able to put my rich experience of medical technologies, orthopaedic service of this Company, whose technology is currently at the phase of commercialization.”
Damian Brown said : “I am delighted to be joining Bone Therapeutics. I look forward to bringing my experience to the strategic development and my skills in cell therapy for the benefit of the Company and its innovative platform of cellular therapy allogeneic, at a key moment before reaching a potential inflection points important “.
About Bone Therapeutics
Bone Therapeutics is a leading company in the cell therapy of bone that meets major unmet medical needs in the field of orthopedics and pathology of bone. Based in Gosselies, Belgium, the Company has an extensive diversified portfolio of cell therapy products bone, in clinical development in various therapeutic areas targeting markets characterized by significant unmet medical needs and innovations limited.
Our technology is based on a unique approach and proprietary in bone regeneration, which transforms stem cells undifferentiated in cell “osteoblastic” or reconstitution of bone tissue. The administration of these cells is achieved in a manner that is minimally invasive which allows to avoid the surgical procedures heavy.
Our clinical program main is ALLOB®, a product of cellular therapy allogeneic “ready-to-use” obtained from stem cells of healthy donors, which is in phase II study in the treatment of fractures with delayed consolidation and in the spinal fusion. The Company also has a cell therapy products autologous bone, PREOB®, is obtained from the own bone marrow of patients, which is currently in Phase III of its development in the osteonecrosis and fractures with failure of consolidation.
The products of cell therapy of Bone Therapeutics are manufactured according to the standards of the GMP the more stringent, and protected by a broad IP portfolio covering nine families of patents. More information are available on our website www.bonetherapeutics.com/fr.
Download the free guide
Boost your gains